miRNA及其靶位点多态性的研究进展

doi:10.3724/SP.J.1005.2010.01091

[an error occurred while processing this directive]

HEREDITAS ›› 2010, Vol. 32 ›› Issue (11): 1091-1096.doi: 10.3724/SP.J.1005.2010.01091

• en • Previous Articles Next Articles

Progress of polymorphism in microRNA and microRNA target sites

LIU Li-Ying¹, XU Ji-Ru², SONG Tu-Sheng³, HUANG Chen³

1. Key Laboratory of Environment and Genes Related to DiseasesMinistry of Education, the Central Laboratory For Biomedical Research, Medical School, Xi’an Jiaotong University, Xi’an 710061, China; 2. Department of Immunology and Microbiology, Medical School, Xi’an Jiaotong University, Xi’an 710061, China; 3. Key Laboratory of Environment and Genes Related to DiseasesMinistry of Education, Department of Genetics and Molecular Biology, Medical School, Xi’an Jiaotong University, Xi’an 710061, China

Received:2010-01-10 Revised:2010-03-23 Online:2010-11-20 Published:2010-11-25
Contact: HUANG Chen E-mail:hchen@mail.xjtu.edu.cn

Abstract

Abstract: MicroRNAs (miRNAs), which are evolutionarily well-conserved, 21- to 23-nucleotide-long, small non-coding RNAs, are widely involved in the regulation of multiple biological processes, such as development, organogenesis, cell proliferation, cell differentiation, and apoptosis. Recent studies have shown that polymorphism in miRNAs and their target sites are closely related to various diseases, such as tumor and cardiological diseases. This review introduces recent progresses on polymorphism in microRNAs and their targeting sites and the related diseases.

Key words: microRNAs, polymorphism, disease

LIU Li-Yang, XU Ji-Ru, SONG Cha-Sheng, HUANG Chen. Progress of polymorphism in microRNA and microRNA target sites[J]. HEREDITAS, 2010, 32(11): 1091-1096.

References

[1] Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics, 2009, 10(3): 399–416. [2] Horikawa Y, Wood CG, Yang HS, Zhao H, Ye YQ, Gu J, Lin J, Habuchi T, Wu XF. Single nucleotide polymor-phisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res, 2008, 14(23): 7956–7962. [3] Yang HS, Dinney CP, Ye YQ, Zhu Y, Grossman HB, Wu XF. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res, 2008, 68(7): 2530–2537. [4] Gottwein E, Cai XZ, Cullen BR. A novel assay for viral microRNA function identifies a single nucleotide poly-morphism that affects Drosha processing. J Virol, 2006, 80(11): 5321–5326. [5] Duan RH, Pak CH, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet, 2007, 16(9): 1124–1131. [6] Wu MQ, Jolicoeur N, Li Z, Zhang LH, Fortin Y, L'Abbe D, Yu ZB, Shen SH. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis, 2008, 29(9): 1710–1716. [7] Mencía Á, Modamio-Høybjør S, Redshaw N, Morín M, Mayo-Merino F, Olavarrieta L, Aguirre LA, del Castillo I, Steel KP, Dalmay T, Moreno F, Moreno-Pelayo MÁ. Mu-tations in the seed region of human miR-96 are responsi-ble for nonsyndromic progressive hearing loss. Nat Genet, 2009, 41(5): 609–613. [8] Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P.Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet, 2009, 46(5): 358–360. [9] Pfister S, Remke M, Castoldi M, Bai AHC, Muckenthaler MU, Kulozik A, von Deimling A, Pscherer A, Lichter P, Korshunov A. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol, 2009, 117(4): 457–464. [10] Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E.miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res, 2009, 69(13): 5553–5559. [11] Diederichs S, Haber DA.Sequence variations of microR-NAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res, 2006, 66(12): 6097–6104. [12] Kontorovich T, Levy A, Korostishevsky M, Nir U, Fried-man E. Single nucleotide polymorphisms in miRNA bind-ing sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer, 2010, 127(3): 589–597. [13] Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casal-ini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Mé-nard S, Croce CM. MicroRNA signatures in human ovarian cancer. Cancer Res, 2007, 67(18): 8699–8707. [14] Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer, 2009, 125(11): 2737–2743. [15] Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LS 4th, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Šestan N, State MW. Sequence variants in SLITRK1 are associated with Tou-rette's syndrome. Science, 2005, 310(5746): 317–320. [16] He HL, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA, 2005, 102(52): 1

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Progress of polymorphism in microRNA and microRNA target sites

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ruijia Song, Lu Han, Haifeng Sun, Bin Shen. Advances in mitochondrial DNA base editing technology [J]. Hereditas(Beijing), 2023, 45(8): 632-642.
[2]	Shan He, Jian Zhao, Xiaofeng Song. Effects of N⁶-methyladenosine modification on the function of the female reproductive system [J]. Hereditas(Beijing), 2023, 45(6): 472-487.
[3]	Xiaokang Shang, Simeng Zhang, Junjun Ni. Research progress of cathepsin B in brain aging and Alzheimer’s diseases [J]. Hereditas(Beijing), 2023, 45(3): 212-220.
[4]	Shuchao Qin, Hua Yin, Rong Wang, Feipeng Zhu, Jianyong Li, Ruinan Lu. Diagnosis, treatment and genetic analysis of an elderly patient with Gaucher’s disease characterized by marked multiple bone destruction [J]. Hereditas(Beijing), 2023, 45(3): 261-269.
[5]	Zhichen Tian, Xiaojuan Yin. Advances in the application of induced pluripotent stem cells in pediatric diseases [J]. Hereditas(Beijing), 2023, 45(1): 42-51.
[6]	Fei Gao, Yu Wang, Jiaxiang Du, Xuguang Du, Jianguo Zhao, Dengke Pan, Sen Wu, Yaofeng Zhao. Advances and applications of genetically modified pig models in biomedical and agricultural field [J]. Hereditas(Beijing), 2023, 45(1): 6-28.
[7]	Fengyu Sun, Qianghua Xu. Research progress of microRNAs involved in hematopoiesis [J]. Hereditas(Beijing), 2022, 44(9): 756-771.
[8]	Juan Wang, Yuening Yang, Weilan Piao, Hua Jin. Uridylation: a vital way for cellular RNA surveillance [J]. Hereditas(Beijing), 2022, 44(6): 449-465.
[9]	Yuan Zhang, Yuting Zhao, Lenan Zhuang, Jin He. Transcriptional regulation of transcriptional Mediator complexes in cardiovascular development and disease [J]. Hereditas(Beijing), 2022, 44(5): 383-397.
[10]	Xueqian Wang, Qingzhen Zhang, Peng Cheng, Tingting Dong, Weiguo Li, Zhe Zhou, Shengqi Wang. Genetic polymorphisms of 66 InDel loci in the Chinese Han population [J]. Hereditas(Beijing), 2022, 44(4): 335-345.
[11]	Wandi Xiong, Kaiyu Xu, Lin Lu, Jiali Li. Research progress on lncRNAs in Alzheimer’s disease [J]. Hereditas(Beijing), 2022, 44(3): 189-197.
[12]	Cong Liu, Jiani Feng, Weiwei Li, Weiwei Zhu, Yunxin Xue, Dai Wang, Xilin Zhao. Maintenance of dNTP pool homeostasis and genomic stability [J]. Hereditas(Beijing), 2022, 44(2): 96-106.
[13]	Wanzi Jiang, Yiwen Xu, Yiwen Wang, Xiaocheng Zhu, Yingyun Gong, Hongwen Zhou, Zhenzhen Fu. Diagnosis and genetic analysis of a case with glycogen storage disease type V caused by compound heterozygous mutations in the PYGM gene [J]. Hereditas(Beijing), 2022, 44(11): 1063-1071.
[14]	Jiaqi Liang, Chang Liu, Wenxiang Zhang, Siyu Chen. Interaction between hepatokines and metabolic diseases [J]. Hereditas(Beijing), 2022, 44(10): 853-866.
[15]	Zhiquan Tang, Li Shi, Jing Xiong. Progress of solute carrier SLC family in nonalcoholic fatty liver disease [J]. Hereditas(Beijing), 2022, 44(10): 881-898.